TargetMol

BN-82451 HCl

Product Code:
 
TAR-T26878
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26878-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26878-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26878-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BN-82451, a cyclooxygenase inhibitor, is used potentially for the treatment of Huntington?s disease.
CAS:
663172-95-0
Formula:
C18H28Cl2N2OS
Molecular Weight:
391.4
Purity:
0.98
SMILES:
Cl.Cl.CC(C)(C)c1cc(cc(c1O)C(C)(C)C)-c1csc(CN)n1

References

1. Spinnewyn B, Mautino G, Marin JG, Rocher MN, Grandoulier AS, Ferrandis E, Auguet M, Chabrier PE. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology. 2011 Mar;60(4):692-700. doi: 10.1016/j.neuropharm.2010.11.019. Epub 2010 Dec 1. PubMed PMID: 21129389. 2. Chabrier PE, Auguet M. Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent. CNS Drug Rev. 2007 Fall;13(3):317-32. Review. PubMed PMID: 17894648. 3. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem. 2003 Jul;86(1):267-72. Erratum in: J Neurochem. 2003 Oct;87(1):272. PubMed PMID: 12807446. 4. Aron Badin R, Spinnewyn B, Gaillard MC, Jan C, Malgorn C, Van Camp N, Doll? F, Guillermier M, Boulet S, Bertrand A, Savasta M, Auguet M, Brouillet E, Chabrier PE, Hantraye P. IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PLoS One. 2013;8(1):e52680. doi: 10.1371/journal.pone.0052680. Epub 2013 Jan 3. PubMed PMID: 23300984; PubMed Central PMCID: PMC3536787.